Cardiac implications in myasthenia gravis

Area of Science:

• Neurology
• Cardiology
• Immunology

Background:

• Reviews current evidence on myasthenia gravis (MG) and cardiac involvement.
• Focuses on thymoma, antistriational antibodies, and late-onset MG.
• Explores genetic population differences influencing cardiac disease risk in MG.

Discussion:

• Strong association found between thymoma, myasthenic crisis, antistriational antibodies, and late-onset MG with cardiac issues.
• Genetic variations impact cardiac disease risk and ECG abnormalities in MG patients.
• Autonomic dysfunction in MG increases susceptibility to arrhythmias and sudden cardiac death.

Key Insights:

• Thymoma, antistriational antibodies, and late-onset MG are significant factors in cardiac involvement.
• Electrocardiography (ECG) is crucial for initial cardiac risk assessment in MG patients.
• Genetic testing may be necessary for comprehensive cardiac risk management.

Outlook:

• Highlights the need for integrated cardiac monitoring in MG patient care.
• Suggests further research into genetic predispositions for cardiac complications in MG.
• Emphasizes proactive cardiac risk management strategies for MG patients, especially perioperatively.